SUMMARY Pre-treatment with erythropoietin (EPO) has been demonstrated to exert tissue-protective effects against ‘ischemia-reperfusion’-type injuries. This protection might be mediated by mobilization of bone marrow endothelial progenitor cells (EPCs), which are thought to secrete paracrine factors. These effects could be exploited to protect against tissue injury induced in cases where hemorrhage is foreseeable, for example, prior to major surgery. Here, we investigate the effects of EPO pre-treatment on the organ injury and dysfunction induced by hemorrhagic shock (HS). Recombinant human EPO (1000 IU/kg/day i.p.) was administered to rats for 3 days. Rats were subjected to HS on day 4 (pre-treatment protocol). Mean arterial pressure was re...
Due to (i) the uremia-enhanced sepsis severity, (ii) the high prevalence of sepsis with pre-existing...
Factors predisposing to extracellular matrix degradation associated with myocardial ischemia/reperfu...
Erythropoietin (EPO) has been proposed as a novel cytoprotectant in ischemia-reperfusion (I/R) injur...
AbstractObjectiveHypertensive patients have higher mortality rates from hemorrhagic shock (HS) than ...
Introduction: The aim of the present study was to evaluate the role of erythropoietin (EPO) in liver...
Erythropoietin (EPO) is a hypoxia-inducible hormone that is essential for normal erythropoiesis in t...
Recently, erythropoietin was shown to have both hematopoietic as well as tissue-protective propertie...
Background: Human recombinant erythropoietin (Epo) has recently been shown to be a potent protector ...
Erythropoietin (EPO) is a hypoxia-inducible hormone that is essential for normal erythropoiesis in t...
de Souza ACCP, Volpini RA, Shimizu MH, Sanches TR, Camara NOS, Semedo P, Rodrigues CE, Seguro AC, An...
Erythropoietin (EPO), a pleiotropic cytokine involved in erythropoiesis, is tissue-protective in isc...
BackgroundBesides its haematopoietic effect, erythropoietin (EPO) has multiple protective effects, i...
Ischemia-reperfusion injury (I/R) is the main cause of primary graft nonfunction. Our aim was to eva...
Previous studies have shown that erythropoietin (EPO) has protective effects against ischemia/reperf...
Aims: Considering the implications that arose from several recent experimental studies using recombi...
Due to (i) the uremia-enhanced sepsis severity, (ii) the high prevalence of sepsis with pre-existing...
Factors predisposing to extracellular matrix degradation associated with myocardial ischemia/reperfu...
Erythropoietin (EPO) has been proposed as a novel cytoprotectant in ischemia-reperfusion (I/R) injur...
AbstractObjectiveHypertensive patients have higher mortality rates from hemorrhagic shock (HS) than ...
Introduction: The aim of the present study was to evaluate the role of erythropoietin (EPO) in liver...
Erythropoietin (EPO) is a hypoxia-inducible hormone that is essential for normal erythropoiesis in t...
Recently, erythropoietin was shown to have both hematopoietic as well as tissue-protective propertie...
Background: Human recombinant erythropoietin (Epo) has recently been shown to be a potent protector ...
Erythropoietin (EPO) is a hypoxia-inducible hormone that is essential for normal erythropoiesis in t...
de Souza ACCP, Volpini RA, Shimizu MH, Sanches TR, Camara NOS, Semedo P, Rodrigues CE, Seguro AC, An...
Erythropoietin (EPO), a pleiotropic cytokine involved in erythropoiesis, is tissue-protective in isc...
BackgroundBesides its haematopoietic effect, erythropoietin (EPO) has multiple protective effects, i...
Ischemia-reperfusion injury (I/R) is the main cause of primary graft nonfunction. Our aim was to eva...
Previous studies have shown that erythropoietin (EPO) has protective effects against ischemia/reperf...
Aims: Considering the implications that arose from several recent experimental studies using recombi...
Due to (i) the uremia-enhanced sepsis severity, (ii) the high prevalence of sepsis with pre-existing...
Factors predisposing to extracellular matrix degradation associated with myocardial ischemia/reperfu...
Erythropoietin (EPO) has been proposed as a novel cytoprotectant in ischemia-reperfusion (I/R) injur...